Quantum BioPharma (QNTM) is partnering with Thermo Fisher Scientific's (TMO) PPD clinical research division to launch a Phase 2 clinical trial for its progressive multiple sclerosis treatment, Lucid-MS. This collaboration marks a significant step forward for QNTM's drug development, leveraging TMO's expertise in clinical trial management.
Quantum BioPharma (QNTM) has reached a critical milestone by advancing its progressive multiple sclerosis drug, Lucid-MS, into a Phase 2 clinical trial. The partnership with Thermo Fisher's (TMO) PPD clinical research business provides QNTM with essential support for study initiation and management, lending credibility and operational strength to the trial. This is a significant positive for QNTM, as successful progression through clinical trials is crucial for biotech companies. For TMO, it represents a routine business win for its clinical research services, contributing to its revenue but unlikely to be a major catalyst. Short-term, QNTM shares could see positive sentiment due to this development, while long-term success hinges on the trial's outcomes. Traders should watch QNTM for continued news on trial progress and results.